Discovery of novel isoform-selective histone deacetylases 5 and 9 inhibitors through combined ligand-based pharmacophore modeling, molecular mocking, and molecular dynamics simulations for cancer treatment

dc.contributor.authorElmezayen, Ammar D.
dc.contributor.authorYelekçi, Kemal
dc.contributor.authorAl-Obaidi, Anas
dc.contributor.authorYelekçi, Kemal
dc.date2021-07
dc.date.accessioned2021-06-12T20:07:36Z
dc.date.available2021-06-12T20:07:36Z
dc.date.issued2021-07
dc.date.issued2021
dc.description.abstractClass IIa histone deacetylases (HDACs) 5 and 9 play crucial roles in several human disorders such as cancer, making them important targets for drug design. Continuous research is pursed to overcome the cytotoxicity side effect that comes with the currently available broad-spectrum HDACs inhibitors. Herein, common features of active HDACs inhibitors in clinical trials and use have been calculated to generate the best pharmacophore hypothesis. Guner-Henry scoring system was used to validate the generated hypotheses. Hypo1 of HDAC5 and Hypo2 of HDAC9 exhibited the most statistically significance hypotheses. Compounds with fit value of 3 and more were examined by QuickVina 2 docking tool to calculate their binding affinity toward all class IIa HDACs. A total of 6 potential selective compounds were subjected to 100 molecular dynamics (MD) simulation to examine their binding modes. The free binding energy calculations were computed according to the MM-PBSA method. Proposed selective compounds displayed good stability with their targets and thus they may offer potent leads for the designing of HDAC5 and HDAC9 isoform selective inhibitors.en_US
dc.identifier.citation2
dc.identifier.doi10.1016/j.jmgm.2021.107937en_US
dc.identifier.issn1093-3263
dc.identifier.issn1093-3263en_US
dc.identifier.pmid34049193en_US
dc.identifier.scopus2-s2.0-85106925494en_US
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://hdl.handle.net/20.500.12469/4041
dc.identifier.volume106en_US
dc.identifier.wosWOS:000661885700003en_US
dc.institutionauthorElmezayen, Ammar D.en_US
dc.institutionauthorAl-Obaidi, Anasen_US
dc.institutionauthorYelekçi, Kemalen_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.journalJournal of Molecular Graphics and Modellingen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHDAC5en_US
dc.subjectHDAC9en_US
dc.subjectMD simulationen_US
dc.subjectMM-PBSAen_US
dc.subjectPharmacophore modelingen_US
dc.titleDiscovery of novel isoform-selective histone deacetylases 5 and 9 inhibitors through combined ligand-based pharmacophore modeling, molecular mocking, and molecular dynamics simulations for cancer treatmenten_US
dc.typeArticleen_US
dspace.entity.typePublication
relation.isAuthorOfPublication9407938e-3d31-453b-9199-aaa8280a66c5
relation.isAuthorOfPublication.latestForDiscovery9407938e-3d31-453b-9199-aaa8280a66c5

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
1-s2.0-S1093326321001066-main.pdf
Size:
8.66 MB
Format:
Adobe Portable Document Format
Description: